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measures of health-related quality of life among people with type 2
diabetes. Methods: Patients participating in the Action in Diabetes
and Vascular Disease:Preterax and Diamicron MR Controlled Evalua-
tion (ADVANCE) trial were administered a health-related quality-of-
life questionnaire, the three-level EuroQol ﬁve-dimensional question-
naire (EQ-5D-3L), on four occasions over a 5-year period. We used two-
way ﬁxed-effects longitudinal regression models to investigate the
impact of incident diabetes complications (stroke, heart failure,
myocardial infarction, ischemic heart disease, renal failure, blindness,
and amputation) on EQ-5D-3L utility score (where 1 ¼ perfect health),
while controlling for characteristics of individuals that do not vary
over time. Results: The effect of having any one of the seven
complications was to reduce the EQ-5D-3L utility score by 0.054 (95%
conﬁdence interval 0.044–0.064), and this was not signiﬁcantly
affected by baseline age, sex, economic region, or the value set usedee front matter Copyright & 2016, International S
r Inc.
.1016/j.jval.2015.10.010
yes@sydney.edu.au.
ndence to: Alison Hayes, Sydney School of Public H
a.to derive utilities. The complication with the largest disutility was
amputation (0.122), followed by stroke (0.099), blindness (0.083), renal
failure (0.049), heart failure (0.045), and myocardial infarction (0.026).
Ischemic heart disease did not signiﬁcantly reduce the utility score.
Quality of life also declined with elapsed time—by an average of 0.006 per
year, in addition to the effect of complications. Conclusions: Common
complications signiﬁcantly reduce health-related quality of life. Utility
scores derived from the EQ-5D-3L provide a potential measure that can
be used to summarize patient-reported outcomes and inform health
economic models. Prevention of complications is critical to reduce the
progressive burden of declining quality of life for people with diabetes.
Keywords: complications, longitudinal analysis, quality of life, type 2
diabetes.
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The quality-adjusted life-year is one of the most widely used
outcome measures used in health economic evaluations [1,2] and
has been advocated as a patient-reported outcome that can assist
in clinical and patient decision making [2,3]. Many studies using
individual participant data therefore aim to estimate the effects
of disease events on health-related quality of life (HRQOL) and
determine utility weights that can be used in cost-utility analy-
ses. Commonly, HRQOL is measured by a utility score in which
full health is assigned a value of 1 and death is assigned a value
of 0. Utility scores can be derived from generic quality-of-life
instruments, including the three-level EuroQol ﬁve-dimensional
questionnaire (EQ-5D-3L), and can be used as weights to calculate
healthy life-years or quality-adjusted life-years [4]. Utility valueshave also been used as a metric for quantifying quality improve-
ment of diabetes management in a clinical setting [2].
Among people with diabetes, a key factor inﬂuencing quality-
adjusted life-years is the degree and nature of diabetes-related
complications experienced by patients over a lifetime [5,6]. Typically,
utilities associated with complications of diabetes have been derived
from cross-sectional data [5,7–12], by comparing those with and
without a history of a complication at a point in time. These values,
however, may be substantially different to longitudinal changes in
HRQOL for individuals who experience complications. For example,
it has been shown that individuals who go on to have complications
already have consistently lower quality of life than do those who do
not [13] and this may contribute to measurement bias [14].
The aim of this study was to determine complication-speciﬁc
measures of utility change, using a large longitudinal data set ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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of follow-up. We examined seven major diabetes-related compli-
cations—stroke, heart failure, myocardial infarction (MI), ische-
mic heart disease, renal failure, blindness, and amputation—and
speciﬁcally investigated homogeneity in quality-of-life decre-
ments associated with complications in different population
subgroups.Methods
Study Population
We used a longitudinal data set based on the Action in Diabetes
and Vascular Disease:Preterax and Diamicron MR Controlled
Evaluation (ADVANCE) trial, which involved 11,140 patients with
type 2 diabetes from 20 high- and middle-income countries in
Australasia, Asia, Europe, and North America [15]. The ADVANCE
study was a multicountry randomized 2  2 factorial trial
involving patients with type 2 diabetes and compared 1) routine
blood pressure lowering based on a perindopril-indapamide
combination with a matching placebo, and 2) intensive
gliclazide-based therapy with usual guideline-based glucose con-
trol therapy. ADVANCE is registered with ClinicalTrials.gov (num-
ber NCT00145925).
Patients were eligible for the trial if they had been diagnosed
with type 2 diabetes mellitus at the age of 30 years or older, were
aged 55 years or older at entry to the study, and had a history of
major macrovascular disease or at least one other risk factor for
macrovascular disease. The eligibility criteria were intentionally
designed to enrol a broad cross-section of high-risk patients [12].
Because this study focuses on quality of life, the analyses
involved 11,130 patients who had completed at least one
quality-of-life questionnaire.
Measurement of Quality of Life
Patient-reported health status was determined using the generic
quality-of-life instrument the EQ-5D-3L, which determines func-
tional status across ﬁve domains— mobility, self-care, usual
activities, anxiety/depression, and pain. Each domain has three
possible levels (i.e., 1, 2, or 3), representing “no problems,” “some
problems,” and “extreme problems,” respectively. Respondents
are asked to choose one level that reﬂects their “own health state
today” for each of the domains. The EQ-5D-3L was administered
to all patients at randomization and then on three further
occasions: at 2 years and 4 years postrandomization and at trial
close-out, representing 5 years of follow-up. Utility scores for all
analyses were derived using the UK value set [16], but sensitivity
analyses were also carried out using region-speciﬁc or alternative
value sets. These included the use of the US valuation of the EQ-
5D-3L [17] for “established market economies,” a value set for
Poland determined from a time trade-off approach for Eastern
Europe [18], and a value set derived for China also using time
trade-off for Asia [19].
Deﬁnition of Outcomes
Nonfatal complications were derived from adverse events records
using International Classiﬁcation of Diseases, Tenth Revision and
procedural codes (see Appendix Table 1 in Supplemental Materi-
als found at http://dx.doi.org/10.1016/j.jval.2015.10.010). These
included the following seven complications: acute MI, stroke,
ischemic heart disease (including angina and coronary athero-
sclerosis), heart failure, blindness, amputation, and renal failure.
We also examined quality-of-life changes associated with “any
complication,” a composite outcome composed of any of the
seven complications above.Statistical Analysis
We used two-way ﬁxed-effects longitudinal regression modeling
to investigate changes in EQ-5D-3L utility score associated with
incident nonfatal complications of diabetes while controlling for
all individual patient characteristics and survey time of the EQ-
5D-3L. The analysis thus controls for differences in individual
characteristics that may affect utility score before complications
occur; for example, women are widely reported to have a lower
mean utility than do men [12]. All analyses were also adjusted for
the effect of elapsed time, which represents increasing age or
duration of diabetes of participants that is independent of
complications. We tested whether time-ﬁxed effects were needed
by adding dummies for EQ-5D-3L survey time and testing
whether they were signiﬁcantly different from 0. Details of the
ﬁxed-effects models are given in the statistical appendix in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.10.010. The initial analysis focused on change in quality of
life associated with any incident complication—a composite
outcome of any of the seven deﬁned complications. We then
tested whether this change in utility was similar for particular
population subgroups deﬁned by sex, baseline age (under or over
65 years), diabetes duration (under or over 7 years), previous
complications status, and region (geographic and economic
classiﬁcations, as used previously: Asia, Eastern Europe, and
established market economies) [20,21]. Second, utility changes
associated with each of the seven separate complications and
with elapsed time were determined. Finally, we investigated,
independently of complications, the impact of baseline age on
the decline in utility associated with elapsed time. A Hausman
test [22] was used to test the ﬁxed-effects model against an
alternative random effects model. We performed Wald tests to
investigate homogeneity of the interaction term dummies.Results
Among the 11,140 participants at baseline, 11,130 (99.9%) had one
or more complete EQ-5D-3L questionnaires, and most partici-
pants (n ¼ 8723 [78%]) had all four completed EQ-5D-3L ques-
tionnaires over the 5 years of follow-up. This amounted to a total
of 39,857 patient EQ-5D-3L records for analysis. Patient character-
istics for the analysis population are presented in Table 1. Thirty-
nine percent of the patients had a microvascular or macro-
vascular complication at baseline, and 12% of the patients had
an incident complication during the 5 years of follow-up. Table 2
describes the EQ-5D-3L utility scores collected at four time points
over 5 years of follow-up. The average EQ-5D-3L utility score at
baseline was 0.82, and this declined to 0.80 at the 5-year follow-
up assessment. In a cross-sectional analysis, EQ-5D-3L utility
scores at baseline were signiﬁcantly different between men and
women (P o 0.001), across different regions (P o 0.001), and by
baseline microvascular and macrovascular complication status
(P o 0.001) (Table 2).
In the ﬁxed-effects longitudinal model, the overall effect of
having any one of the seven complications during follow-up was
a permanent utility decrement of 0.054 (95% conﬁdence interval
[CI] 0.044–0.064). There was no signiﬁcant effect of baseline age
(P ¼ 0.362), sex (P ¼ 0.281), diabetes duration (P ¼ 0.351), history
of microvascular or macrovascular disease (P ¼ 0.231), or region
(P ¼ 0.179) on this overall utility decrement (Fig. 1). The Hausmann
test strongly rejected the null hypothesis of equal coefﬁcients in
the ﬁxed-effects and random-effects models (P o 0.001). Figure 2
shows the effects of elapsed time and complications on change in
EQ-5D-3L utility scores. The complication with the largest decre-
ment in utility score was amputation (0.122), followed by stroke
(0.099), blindness (0.083), renal failure (0.049), heart failure (0.045),
Table 1 – Characteristics of study participants.
Characteristic Participants
(N ¼ 11,130)
Age at baseline (y) 65.8 (6.4)
Duration of diabetes at baseline (y) 7.9 (6.4)
Sex
Male 6401 (57)
Female 4729 (43)
Microvascular or macrovascular disease
History at baseline 4349 (39)
No history at baseline 6781 (61)
Region
Eastern Europe 2142 (19)
Asia 4136 (37)
Established market economies 4852 (44)
Patients with incident nonfatal events
Any nonfatal event 1366 (12.0)
MI 247 (2.2)
Stroke 335 (3.0)
Heart failure 270 (2.4)
IHD 483 (4.4)
Blindness 44 (0.4)
Amputation 39 (0.3)
Renal failure 89 (0.8)
Values are mean (SD) or n (%).
IHD, ischemic heart disease; MI, myocardial infarction.
Table 2 – Summary statistics of EQ-5D-3L utility scores at
economic region, history of macrovascular/microvascula
valuation of the EQ-5D-3L and sensitivity analysis using
Population category Baseline (N ¼ 11,081)
All patients 0.82  0.19
Sex†
Men 0.84  0.18
Women 0.79  0.20
Age at baseline
o65 y 0.82  0.19
Z65 y 0.82  0.20
Duration of diabetes at baseline
o7 y 0.82  0.19
Z7 y 0.82  0.20
Microvascular or macrovascular
disease at baseline†
Yes 0.80  0.21
No 0.83  0.18
Region (UK valuation of EQ-5D-3L)†
Eastern Europe 0.76  0.21
Asia 0.85  0.16
Established market economies 0.82  0.20
Region (alternative valuation of EQ-5D-3L)*
Eastern Europe 0.86  0.21
Asia 0.89  0.16
Established market economies 0.86  0.20
EQ-5D-3L, three-level, EuroQol ﬁve-dimensional questionnaire.
* Region-speciﬁc valuations used were the Polish value set for Eastern Eur
market economics.
† Mean utilities at baseline survey signiﬁcantly different (P o 0.001) acro
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ment (0.01), but this was not signiﬁcantly different from 0. Across
all patients, utility change across time and independent of
complications at 2-, 4-, and 5-year follow-up was a reduction of
0.017, 0.026, and 0.030, respectively. Further stratiﬁcation by
baseline age showed that loss of quality of life over time was
greater for older participants. Based on 5 years of follow-up, the
average (95% CI) utility decrement for patients who were 50 to 59
years old at baseline was 0.018 (0.011–0.026), for those 60 to 69
years old was 0.023 (0.018–0.029), and for those older than 70
years at baseline was 0.043 (0.035–0.05).
The sensitivity analysis, using region-speciﬁc EQ-5D-3L value
sets, indicated higher mean EQ-5D-3L utility scores than those
using the UK valuation, for all regions (P o 0.001). Using utilities
from the alternative value sets in the two-way ﬁxed-effects
model, the mean (95% CI) utility decrement associated with
“any complication” was 0.046 (0.052–0.039), which was not sig-
niﬁcantly different (P ¼ 0.182) from the value of 0.054 (0.044–0.064)
determined in the main analysis using the UK valuation.Conclusions
A longitudinal regression analysis using up to 5 years of data on
more than 11,000 patients with type 2 diabetes from the
ADVANCE study indicated that complications had a permanent
impact on EQ-5D-3L utility scores, a health-related measure of
quality of life. At baseline, the average EQ-5D-3L score was 0.827
(95% CI 0.824–0.830) and for those experiencing events thefour time assessments, and overall, stratiﬁed by sex,
r disease, age, and duration of diabetes, using UK
region-speciﬁc valuations*.
EQ-5D-3L utility score, mean  SD
2 y (N ¼ 10,301) 4 y (N ¼ 9,532) 5 y (N ¼ 8,943)
0.81  0.22 0.80  0.22 0.80  0.22
0.83  0.20 0.82  0.21 0.82  0.21
0.77  0.23 0.76  0.23 0.76  0.23
0.82  0.21 0.82  0.21 0.82  0.21
0.79  0.22 0.78  0.23 0.78  0.23
0.81  0.21 0.81  0.21 0.81  0.21
0.80  0.22 0.79  0.22 0.79  0.23
0.79  0.23 0.78  0.24 0.78  0.23
0.82  0.20 0.81  0.21 0.81  0.22
0.75  0.23 0.74  0.23 0.74  0.24
0.84  0.19 0.84  0.20 0.84  0.20
0.80  0.22 0.79  0.23 0.78  0.23
0.85  0.23 0.85  0.23 0.85  0.24
0.88  0.19 0.87  0.20 0.87  0.20
0.85  0.22 0.84  0.23 0.83  0.23
ope, a Chinese value set for Asia, and the US value set for established
ss categories.
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No history micro/ macro (n=648)
History micro/macro (n=748)
> 7 years diabetes (n=758)
≤ 7 years diabetes (n=608)
> 65 years (n=873)
<  65 years (n=493)
Male (n=870)
Female (n=496)
Any complication (n=1366) -0.054 (-0.064, -0.044)
-0.059 (-0.073, -0.044)
-0.048 (-0.061, -0.035)
-0.048 (-0.061, -0.035)
-0.057 (-0.069, -0.045)
-0.064 (-0.088, -0.041)
-0.045 (-0.058, -0.031)
-0.061 (-0.076, -0.046)
-0.050 (-0.062, -0.038)
-0.061 (-0.076, -0.045)
-0.049 (-0.063, -0.035)
-0.058 (-0.071, -0.045)
mean (95% CI) utility change
mean (95% CI) p value
p=0.281
p=0.231
p=0.179
p=0.362
p=0.351
Fig. 1 – Two-way ﬁxed-effects model β coefﬁcients for utility change associated with incident complications of diabetes
(composite of seven complications), and in ﬁve additional models in which complications were stratiﬁed by baseline age, sex,
diabetes duration, history of microvascular or macrovascular complications, and economic region. All models were adjusted
for the time of the EQ-5D-3L survey and individual patient effects. CI, conﬁdence interval; EME, established market economy;
EQ-5D-3L, three-level, EuroQol ﬁve-dimensional questionnaire.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 3 6 – 4 1 39estimated additional decrement associated with an incident
complication was 0.054 (95% CI 0.044–0.064). The EQ-5D-3L utility
decrement for incident complications was not signiﬁcantly
affected by the baseline characteristics of patients, nor by the
use of region-speciﬁc or alternative valuations for the EQ-5D-3L.-0.2 -0.1 0.0
Amputation
Stroke
Blindness
Renal failure
CHF
MI
IHD
5 elapsed years
4 elapsed years
2 elapsed years
Ti
m
e 
 e
ffe
ct
s
C
om
pl
ic
at
io
n 
 e
ffe
ct
s
mean (95% CI) util
Fig. 2 – Two-way ﬁxed-effects model β coefﬁcients for utility chan
complications. CHF, congestive heart failure; CI, conﬁdence inteOur estimate of the utility decrement for any complication was
very similar to that determined in a longitudinal analysis of
quality-of-life data from the United Kingdom Prospective Diabe-
tes Study [14]; however, baseline utility was much lower in
that study.0.1 0.2
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ge associated with elapsed time and seven nonfatal diabetes
rval; IHD, ischemic heart disease; MI, myocardial infarction.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 3 6 – 4 140The individual complication with the largest overall reduction
on utility score was amputation (0.122), followed by stroke (0.099),
blindness (0.083), renal failure (0.049), heart failure (0.044), and MI
(0.025). The nonsigniﬁcant impact of ischemic heart disease on
quality of life may be attributed to modern treatments (e.g.,
stents), which are very effective in controlling angina and allow-
ing survivors to quickly get back to normal life. Our results agree
broadly with those of many other studies [6,7,11,23] in that the
largest changes in quality of life were for amputation, stroke, and
loss of vision. The complication-speciﬁc utility decrements deter-
mined in this study, however, were generally lower than those
previously reported [5]—this probably reﬂects the differing meth-
odologies used (longitudinal vs. cross-sectional). As noted by Alva
et al. [14], cross-sectional studies are likely to overestimate the
impact of complications on utility score, whereas in the ﬁxed-
effects model, subjects serve as their own controls, allowing us to
isolate the effect of complications from other patient-speciﬁc
effects.
We have also shown that elapsed time (which represents
aging and increasing duration of diabetes) has a signiﬁcant effect
on quality-of-life changes with an average decrement of around
0.03 over the full 5-year duration of the study, or 0.006 per
annum. This effect of declining quality of life with aging is
independent of complications and accelerates at older ages. For
example, for patients in their ﬁfties, the utility decrement over
the 5-year study was 0.018 or 0.003 per annum, whereas for
patients in their sixties it was 0.023 over 5 years or 0.005 per
annum and for those older than 70 years at baseline the
decrement was 0.043 in 5 years, or 0.008 per annum. The age
effects appear consistent with reported population norms such as
those for the United Kingdom (https://www.york.ac.uk/media/
che/documents/papers/discussionpapers/CHE%20Discussion%
20Paper%20172.pdf) and provide a useful means to compare the
effects of complications. For example, the results of our study
suggest that the long-term impact of heart failure on quality of
life is equivalent to around 5 years of aging, whereas an MI was
equivalent to around 2.5 years and a stroke equivalent to around
10 years of aging for someone in their seventies.
Our study has also highlighted the issue of which value set to
use in determining utility scores from a generic quality-of-life
survey instrument. Mean EQ-5D-3L utility scores differed depend-
ing on the value set used, most notably for patients from Eastern
Europe, where the mean (SD) EQ-5D-3L utility score at baseline
was 0.76 (0.21) using the UK value set [16] and 0.86 (0.21) using the
Polish [18] value set. Despite these differences in mean values,
the ﬁxed-effects longitudinal model found no signiﬁcant differ-
ences in the change in utility associated with incident complica-
tions, regardless of which value set was used, thus reinforcing
the ﬁnding that there is no effect of geographic region on quality-
of-life changes associated with complications.
A previous analysis based on the ADVANCE study [20] showed
substantial variation across patients from different regions in
their responses to the items that make up the EQ-5D-3L, with
those in Eastern Europe reporting a higher level of problems on
most dimensions of the EQ-5D-3L. Using the UK valuation of the
EQ-5D-3L, these translated into lower utility scores of people
from Eastern Europe compared with people in Asia or in estab-
lished market economies. The results in our study suggest that
these apparent differences may be ameliorated by using the
appropriate value set for the region.
The major strength of our study is the sophisticated analysis
of a large and very rich longitudinal data set, with repeated EQ-
5D-3L measurements on the same individuals over 5 years,
totaling more than 39,000 records and thus enabling the elucida-
tion of the impact of diabetes complications on HRQOL over any
background noise in the data. We used a ﬁxed-effects rather than
random-effects model because previous work has indicated thatpatients who go on to have complications are systematically
different from those who do not. We also found an effect of
declining utility related to aging, something that has not usually
been accounted for in modeled economic evaluations. This aging
effect is in addition to the effect of complications, due to the
additive speciﬁcation of the model.
One limitation of our analysis is that we did not investigate
the effects of multiple complications of the same type, but
analyzed ﬁrst events only. Recurrent events were not deﬁned
trial outcomes in ADVANCE, but we estimated that only a very
small proportion of participants (o0.5%) were likely to have two
nonfatal events of the same type during the follow-up period. We
were able, however, to investigate the effect of multiple different
complications, and the effect on utility was additive. Another
limitation is that we were not able to take account of severity of
complications, and we did not separate acute changes in utility
from long-term changes. Finally, data informing these analyses
are from a randomized clinical trial population and may not be
representative of the wider population with type 2 diabetes.
Despite cross-sectional differences in levels of mean utility at
baseline across sex, complication status, and economically
deﬁned regions of the world, the longitudinal decrements in
quality of life related to incident diabetes complications were
homogeneous. Longitudinal changes in quality of life were also
insensitive to the value set used to derive utility scores. The
implication for health economic modeling is that a similar set of
utility decrements for complications may be used for patients
across different regions, of different ages and with different
comorbidities, even though these patients may differ in their
baseline level of quality of life. A novel ﬁnding was to quantify
the loss in utility attributable to aging but independent of
complications, which is usually unaccounted for in health eco-
nomic models.
Utility scores derived from the EQ-5D-3L provide a potential
measure to summarize patient-reported outcomes and inform
health economic simulation models [24]. Prevention of compli-
cations is critical to reduce the progressive burden of declining
quality of life for people with diabetes.
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